S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
NASDAQ:JNCE

Jounce Therapeutics Stock Competitors

$7.13
-0.48 (-6.31%)
(As of 12/3/2021 12:00 AM ET)
Add
Compare
Today's Range
$7.11
$7.64
50-Day Range
$7.13
$9.64
52-Week Range
$5.03
$14.84
Volume
349,798 shs
Average Volume
582,905 shs
Market Capitalization
$365.34 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.05

Jounce Therapeutics (NASDAQ:JNCE) Vs. INBX, CHRS, RGNX, REPL, IMCR, ITOS, SGMO, OCGN, ALVR, and RUBY

Should you be buying Jounce Therapeutics stock or one of its competitors? The main competitors of Jounce Therapeutics include Inhibrx (INBX), Coherus BioSciences (CHRS), REGENXBIO (RGNX), Replimune Group (REPL), Immunocore (IMCR), iTeos Therapeutics (ITOS), Sangamo Therapeutics (SGMO), Ocugen (OCGN), AlloVir (ALVR), and Rubius Therapeutics (RUBY). These companies are all part of the "biological products, except diagnostic" industry.

Jounce Therapeutics vs.

Jounce Therapeutics (NASDAQ:JNCE) and Coherus BioSciences (NASDAQ:CHRS) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, community ranking, risk, institutional ownership, profitability, valuation, earnings, media sentiment and analyst recommendations.

75.5% of Jounce Therapeutics shares are owned by institutional investors. 5.3% of Jounce Therapeutics shares are owned by company insiders. Comparatively, 13.0% of Coherus BioSciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Coherus BioSciences received 140 more outperform votes than Jounce Therapeutics when rated by MarketBeat users. However, 69.27% of users gave Jounce Therapeutics an outperform vote while only 67.04% of users gave Coherus BioSciences an outperform vote.

CompanyUnderperformOutperform
Jounce TherapeuticsOutperform Votes
275
69.27%
Underperform Votes
122
30.73%
Coherus BioSciencesOutperform Votes
415
67.04%
Underperform Votes
204
32.96%

In the previous week, Jounce Therapeutics and Jounce Therapeutics both had 1 articles in the media. Jounce Therapeutics' average media sentiment score of 0.66 beat Coherus BioSciences' score of 0.59 indicating that Jounce Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Jounce Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Coherus BioSciences
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Jounce Therapeutics currently has a consensus price target of $15.67, suggesting a potential upside of 119.73%. Coherus BioSciences has a consensus price target of $25.75, suggesting a potential upside of 45.07%. Given Jounce Therapeutics' higher probable upside, equities analysts plainly believe Jounce Therapeutics is more favorable than Coherus BioSciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Jounce Therapeutics
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
3.00
Coherus BioSciences
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00

Jounce Therapeutics has a net margin of 0.00% compared to Coherus BioSciences' net margin of -63.72%. Jounce Therapeutics' return on equity of -9.86% beat Coherus BioSciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Jounce Therapeutics N/A -9.86% -8.86%
Coherus BioSciences -63.72% -133.21% -30.72%

Jounce Therapeutics has a beta of 1.05, suggesting that its share price is 5% more volatile than the S&P 500. Comparatively, Coherus BioSciences has a beta of 0.97, suggesting that its share price is 3% less volatile than the S&P 500.

Coherus BioSciences has higher revenue and earnings than Jounce Therapeutics. Jounce Therapeutics is trading at a lower price-to-earnings ratio than Coherus BioSciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Jounce Therapeutics$62.34 million5.86-$43.84 million-$0.39-18.28
Coherus BioSciences$475.82 million2.86$132.24 million-$3.14-5.65

Summary

Jounce Therapeutics beats Coherus BioSciences on 11 of the 16 factors compared between the two stocks.


New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding JNCE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment >-1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

Jounce Therapeutics (NASDAQ:JNCE) vs. Its Competitors

TypeJounce TherapeuticsBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$365.34M$3.72B$4.91B$7.73B
Dividend YieldN/A2.15%2.07%2.53%
P/E Ratio-18.286.6818.1720.60
Price / Sales5.862,643.602,451.89252.07
Price / CashN/A103.0564.68178.65
Price / Book1.454.986.337.20
Net Income-$43.84M$2.48M$95.98M$154.04M
7 Day Performance-12.30%-7.52%-6.31%-5.42%
1 Month Performance-25.81%-18.82%-15.24%-11.74%
1 Year Performance2.74%-8.99%7.55%21.43%

Jounce Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
INBX
Inhibrx
2.1331 of 5 stars
$36.90
-8.0%
$53.00
-43.6%
+5.5%$1.40B$12.89M-17.8388Analyst Downgrade
Short Interest ↓
News Coverage
CHRS
Coherus BioSciences
2.0648 of 5 stars
$17.75
-1.7%
$25.75
-45.1%
-4.6%$1.36B$475.82M-5.65317
RGNX
REGENXBIO
2.4873 of 5 stars
$30.59
-3.4%
$58.25
-90.4%
-19.3%$1.31B$154.57M-5.92306
REPL
Replimune Group
2.3865 of 5 stars
$27.66
-4.8%
$55.00
-98.8%
-38.7%$1.30BN/A-14.26152
IMCR
Immunocore
1.5082 of 5 stars
$28.71
-11.9%
$54.75
-90.7%
N/A$1.24B$38.67M0.002,020News Coverage
High Trading Volume
ITOS
iTeos Therapeutics
2.5348 of 5 stars
$34.82
-0.7%
$46.25
-32.8%
+22.2%$1.23BN/A120.0762Analyst Downgrade
Insider Selling
Short Interest ↓
SGMO
Sangamo Therapeutics
1.8881 of 5 stars
$8.10
-4.3%
$23.00
-184.0%
-17.8%$1.18B$118.19M-6.38413Insider Selling
OCGN
Ocugen
1.8914 of 5 stars
$5.76
-9.5%
$7.90
-37.2%
+1,802.9%$1.15B$42.62M0.0015
ALVR
AlloVir
2.2998 of 5 stars
$17.49
-3.6%
$46.67
-166.8%
-60.3%$1.14B$170K0.0053
RUBY
Rubius Therapeutics
2.0998 of 5 stars
$12.07
-4.5%
$26.33
-118.2%
+77.8%$1.08BN/A-5.69204
HUMA
Humacyte
2.4917 of 5 stars
$10.39
-5.3%
$17.25
-66.0%
N/A$1.07BN/A0.00N/A
CRBU
Caribou Biosciences
1.9848 of 5 stars
$17.07
-5.5%
$30.60
-79.3%
N/A$1.03BN/A0.002,021Analyst Report
Short Interest ↑
Analyst Revision
News Coverage
PCVX
Vaxcyte
1.6065 of 5 stars
$19.32
-5.6%
N/A-35.6%$1.02BN/A-10.7958
SRRK
Scholar Rock
2.3865 of 5 stars
$25.10
-2.6%
$65.00
-159.0%
-42.1%$881.21M$15.40M-7.36119
IMVT
Immunovant
1.9667 of 5 stars
$7.60
-4.3%
$16.00
-110.5%
-84.9%$874MN/A-5.9868
IPSC
Century Therapeutics
1.7048 of 5 stars
$15.23
-2.8%
$36.00
-136.4%
N/A$832.17MN/A0.00102
GRTS
Gritstone bio
2.3998 of 5 stars
$11.58
-5.4%
$22.33
-92.9%
+289.9%$830.13M$4.04M-9.05169Options Volume
BCAB
BioAtla
2.5333 of 5 stars
$22.50
-2.2%
$65.20
-189.8%
N/A$828.90M$430K0.0036Insider Selling
High Trading Volume
ICVX
Icosavax
1.825 of 5 stars
$21.07
-2.8%
$48.57
-130.5%
N/A$822.57MN/A0.002,021
SOPH
SOPHiA Genetics
1.7 of 5 stars
$12.91
-1.2%
$23.00
-78.2%
N/A$817.69M$28.40M0.00N/A
VXRT
Vaxart
1.8464 of 5 stars
$6.32
-5.9%
$13.75
-117.6%
-18.1%$793.14M$4.05M-11.7028
TNYA
Tenaya Therapeutics
1.7048 of 5 stars
$18.89
-5.1%
$36.00
-90.6%
N/A$779.80MN/A0.002,021
MGTX
MeiraGTx
2.4514 of 5 stars
$17.54
-5.6%
$26.50
-51.1%
+25.5%$779.65M$15.56M-9.53219Short Interest ↑
GLUE
Monte Rosa Therapeutics
1.3915 of 5 stars
$16.28
-5.2%
$32.00
-96.6%
N/A$757.18MN/A0.0060
OMGA
Omega Therapeutics
1.6681 of 5 stars
$15.70
-12.9%
$29.50
-87.9%
N/A$750.07MN/A0.002,021
AGEN
Agenus
2.1598 of 5 stars
$2.92
-3.4%
$11.00
-276.7%
-13.9%$749.94M$88.17M-24.33359Analyst Upgrade
FNCH
Finch Therapeutics Group
1.5798 of 5 stars
$15.32
-5.3%
$29.33
-91.5%
N/A$727.39MN/A0.00131
STRO
Sutro Biopharma
2.0531 of 5 stars
$15.56
-4.4%
$30.83
-98.2%
-8.5%$719.96M$42.72M-5.29192
CGEM
Cullinan Oncology
2.5333 of 5 stars
$16.21
-6.0%
$51.75
-219.2%
N/A$708.22MN/A0.0024
BLUE
bluebird bio
2.3698 of 5 stars
$9.95
-6.8%
$18.07
-81.6%
-78.8%$697.59M$250.73M-0.781,213
IMTX
Immatics
1.7 of 5 stars
$10.87
-4.4%
$27.00
-148.4%
+0.7%$683.83M$35.70M0.002,020
FMTX
Forma Therapeutics
1.9664 of 5 stars
$14.30
-3.6%
$60.17
-320.7%
-67.2%$677.82M$100.56M-4.37105Analyst Downgrade
Short Interest ↓
News Coverage
MESO
Mesoblast
1.9317 of 5 stars
$5.21
-5.0%
$13.50
-159.1%
-66.9%$675.95M$7.46M-6.68102Analyst Downgrade
ADAP
Adaptimmune Therapeutics
1.9531 of 5 stars
$3.58
-4.2%
$8.40
-134.6%
-20.4%$559.20M$3.96M-3.622,020
ALGS
Aligos Therapeutics
2.1864 of 5 stars
$13.04
-5.1%
$35.33
-171.0%
-22.9%$555.63MN/A-3.8480
AURA
Aura Biosciences
1.825 of 5 stars
$18.61
-2.8%
$37.67
-102.4%
N/A$543.60MN/A0.00N/AQuiet Period Expiration
Analyst Revision
TALS
Talaris Therapeutics
2.1181 of 5 stars
$12.75
-6.7%
$29.50
-131.4%
N/A$527.28MN/A0.0082Short Interest ↑
News Coverage
GRPH
Graphite Bio
2.4514 of 5 stars
$8.82
-0.6%
$34.67
-293.0%
N/A$512.27MN/A0.0027
TARS
Tarsus Pharmaceuticals
2.4731 of 5 stars
$24.72
-5.2%
$55.00
-122.5%
+11.1%$511.14MN/A0.0020Insider Selling
DTIL
Precision BioSciences
1.9414 of 5 stars
$8.19
-6.5%
$22.00
-168.6%
-19.9%$497.71M$24.28M-13.65231
AERI
Aerie Pharmaceuticals
1.7864 of 5 stars
$10.22
-1.4%
$23.66
-131.5%
-19.2%$484.02M$83.14M-2.83365Short Interest ↓
News Coverage
High Trading Volume
TSHA
Taysha Gene Therapies
2.5333 of 5 stars
$12.45
-5.1%
$46.45
-273.1%
-38.6%$479.00MN/A0.0038Analyst Report
IKNA
Ikena Oncology
1.7381 of 5 stars
$12.00
-7.7%
$27.00
-125.0%
N/A$463.92MN/A0.0033
ATHA
Athira Pharma
2.1064 of 5 stars
$12.34
-5.9%
$51.00
-313.3%
-49.4%$460.90MN/A-9.5721Short Interest ↑
PSTX
Poseida Therapeutics
2.4398 of 5 stars
$7.07
-2.1%
$29.50
-317.3%
-36.6%$441.92MN/A-2.70206Analyst Downgrade
Insider Buying
Short Interest ↓
Positive News
Gap Up
MOLN
Molecular Partners
1.805 of 5 stars
$13.61
-0.1%
$26.51
-94.8%
N/A$439.33M$9.97M0.00152Short Interest ↑
Gap Up
SABS
SAB Biotherapeutics
2.0333 of 5 stars
$9.88
-4.5%
$20.33
-105.8%
N/A$429.53MN/A0.005Analyst Report
News Coverage
AUTL
Autolus Therapeutics
1.5464 of 5 stars
$5.76
-7.8%
$14.67
-154.6%
-45.5%$420.02M$1.72M-2.522,020Short Interest ↑
CRIS
Curis
1.9398 of 5 stars
$4.49
-6.2%
$19.80
-341.0%
+124.5%$411.33M$10.84M-9.7628Analyst Downgrade
CRTX
Cortexyme
2.6481 of 5 stars
$13.04
-8.0%
$38.50
-195.2%
-72.8%$389.64MN/A-4.4438
This page was last updated on 12/4/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.